AbbVie Inc. $ABBV Shares Sold by Genus Capital Management Inc.

Genus Capital Management Inc. lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 60.2% in the second quarter, HoldingsChannel reports. The fund owned 27,370 shares of the company’s stock after selling 41,395 shares during the period. Genus Capital Management Inc.’s holdings in AbbVie were worth $5,080,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the business. TKG Advisors LLC boosted its position in AbbVie by 4.7% during the 2nd quarter. TKG Advisors LLC now owns 12,373 shares of the company’s stock worth $2,297,000 after acquiring an additional 561 shares during the period. Cherry Creek Investment Advisors Inc. boosted its position in AbbVie by 0.4% during the 2nd quarter. Cherry Creek Investment Advisors Inc. now owns 28,233 shares of the company’s stock worth $5,241,000 after acquiring an additional 112 shares during the period. Blue Barn Wealth LLC lifted its holdings in shares of AbbVie by 11.3% in the second quarter. Blue Barn Wealth LLC now owns 1,425 shares of the company’s stock valued at $264,000 after buying an additional 145 shares during the period. Commonwealth Retirement Investments LLC lifted its holdings in shares of AbbVie by 4.5% in the second quarter. Commonwealth Retirement Investments LLC now owns 52,296 shares of the company’s stock valued at $9,707,000 after buying an additional 2,267 shares during the period. Finally, FWG Holdings LLC lifted its holdings in shares of AbbVie by 16.1% in the second quarter. FWG Holdings LLC now owns 2,256 shares of the company’s stock valued at $445,000 after buying an additional 313 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ABBV. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. UBS Group set a $251.00 price objective on AbbVie in a report on Friday, October 3rd. Finally, Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $237.81.

AbbVie Trading Up 1.9%

Shares of NYSE ABBV opened at $216.09 on Wednesday. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81. The company has a market cap of $381.73 billion, a price-to-earnings ratio of 102.90, a P/E/G ratio of 1.42 and a beta of 0.51. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The business has a fifty day simple moving average of $222.66 and a 200-day simple moving average of $201.73.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Insider Activity at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.